Screener / SEC EDGAR /CIK 0001628171 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Revolution Medicines, Inc. RVMD

Compare with peers Embed
Planned sales, announced before they happen

13 trading plans running, 59 Form 144 notices for $161.3M

10-Q, 10-K and Form 144
Plans running now 13 Margaret Horn, J.D, Flavia Borellini, Steve Kelsey, M.D, Jack Anders, Elizabeth Anderson, Anthony Mancini,, Jeff Cislini, Mark A. Goldsmith, Sushil Patel, Margaret Horn
Plans adopted 33 reported since May 8, 2023 Form 144 notices 59 $161.3M the sellers expected to sell

What RVMD's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 22, 2026 to Nov 17, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Margaret Horn, J.D
Chief Operating Officer
Adopted 10b5-1 plan Sep 9, 2026 10-Q Nov 4, 2026
Flavia Borellini
a member of our board of directors
Adopted 10b5-1 plan Aug 20, 2026 10-Q Nov 4, 2026
Steve Kelsey, M.D
President, Research and Development
Adopted 10b5-1 plan Aug 17, 2026 10-Q Nov 4, 2026
Jack Anders
Chief Financial Officer
Adopted 10b5-1 plan Aug 12, 2026 10-Q Nov 4, 2026
Elizabeth Anderson
a member of our board of directors
Adopted 10b5-1 plan Jun 23, 2026 10-Q Nov 4, 2026
Anthony Mancini,
Chief Global Commercialization Officer
Adopted 10b5-1 plan Jun 15, 2026 10-Q Aug 5, 2026
Alan Sandler, M.D
Chief Development Officer
Adopted 10b5-1 plan Jun 14, 2026 10-Q Aug 5, 2026
Steve Kelsey, M.D
President, Research and Development
Adopted 10b5-1 plan Jun 12, 2026 10-Q Aug 5, 2026
Jeff Cislini
Senior Vice President, General Counsel and Secretary
Adopted 10b5-1 plan May 22, 2026 10-Q Aug 5, 2026
Mark A. Goldsmith
President and Chief Executive Officer and Chair of the Board of Directors
Adopted 10b5-1 plan May 22, 2026 10-Q Aug 5, 2026
Sushil Patel
a member of our board of directors
Adopted 10b5-1 plan Mar 30, 2026 10-Q May 6, 2026
Jack Anders
Chief Financial Officer
Adopted 10b5-1 plan Mar 24, 2026 10-Q May 6, 2026
Margaret Horn
Chief Operating Officer
Adopted 10b5-1 plan Mar 12, 2026 10-Q May 6, 2026
Wei Lin
M.D., our Chief Medical Officer
Adopted 10b5-1 plan Dec 16, 2025 10-K Feb 25, 2026
Mark A. Goldsmith
M.D., Ph.D., our President and Chief Executive Officer and Chair of the Board of Directors
Adopted 10b5-1 plan Nov 25, 2025 10-K Feb 25, 2026
Jeff Cislini
Senior Vice President, General Counsel and Secretary
Adopted 10b5-1 plan Mar 13, 2025 10-Q May 7, 2025
Margaret Horn
Chief Operating Officer
Adopted 10b5-1 plan Mar 7, 2025 10-Q May 7, 2025
Steve Kelsey
M.D., FRCP, FRCPath, President, Research and Development
Adopted 10b5-1 plan Feb 28, 2025 10-Q May 7, 2025
Wei Lin
M.D., our Chief Medical Officer
Adopted 10b5-1 plan Dec 23, 2024 10-K Feb 26, 2025
Mark A. Goldsmith
M.D., Ph.D., our President and Chief Executive Officer and Chair of the Board of Directors
Adopted 10b5-1 plan Dec 19, 2024 10-K Feb 26, 2025
Jack Anders
Chief Financial Officer
Adopted 10b5-1 plan Dec 16, 2024 10-K Feb 26, 2025
Wei Lin
M.D., Chief Medical Officer
Ended 10b5-1 plan Aug 2, 2024 10-Q Aug 7, 2024
Barbara Weber
M.D., a member of our board of directors
Adopted 10b5-1 plan May 29, 2024 10-Q Aug 7, 2024
Margaret Horn
J.D., Chief Operating Officer
Adopted 10b5-1 plan Mar 22, 2024 10-Q Aug 7, 2024
Wei Lin
M.D., the Company’s Chief Medical Officer
Adopted 10b5-1 plan Mar 21, 2024 10-Q May 8, 2024
Jeff Cislini
Senior Vice President, General Counsel and Secretary
Adopted 10b5-1 plan Mar 20, 2024 10-Q Aug 7, 2024
Steve Kelsey
M.D., FRCP, FRCPath, President, Research and Development
Adopted 10b5-1 plan Mar 15, 2024 10-Q Aug 7, 2024
Jack Anders
Chief Financial Officer
Adopted 10b5-1 plan Mar 14, 2024 10-Q Aug 7, 2024
Sushil Patel
Ph.D., a member of our board of directors
Adopted 10b5-1 plan Sep 7, 2023 10-Q Aug 7, 2024
Jack Anders
Chief Financial Officer
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 8, 2023
Jeff Cislini
Senior Vice President, General Counsel and Secretary
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 8, 2023
Margaret Horn
J.D., Chief Operating Officer
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 8, 2023
Mark A. Goldsmith
M.D., Ph.D., Chair of the Board, Chief Executive Officer and President
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 8, 2023
Steve Kelsey
M.D., FRCP, FRCPath, President, Research and Development
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 8, 2023
Show the other 26 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 12, 2026 JACK LEE ANDERS
Officer
35,750 $6.9M
Sep 29, 2026 ALAN SANDLER
Officer
6,309 $1.3M
Sep 25, 2026 ANTHONY MANCINI
Officer
9,363 $1.9M
Sep 24, 2026 ANTHONY MANCINI
Officer
587 $112K
Sep 22, 2026 Elizabeth Anderson
Director
15,080 $2.9M
Sep 18, 2026 ANTHONY MANCINI
Officer
1,764 $347K
Sep 15, 2026 Mancini Anthony
Officer
2,377 $484K
Sep 15, 2026 Cislini Jeff
Officer
3,272 $667K
Sep 15, 2026 Sandler Alan B
Officer
331 $67K
Sep 15, 2026 Anders Jack
Officer
3,939 $803K
Sep 15, 2026 Kelsey Stephen Michael
Officer
5,415 $1.1M
Sep 15, 2026 Horn Margaret A
Officer
4,830 $984K
Sep 15, 2026 Goldsmith Mark A
Officer, Director
13,603 $2.8M
Sep 11, 2026 STEPHEN KELSEY
Officer
92,531 $18.8M
Sep 10, 2026 ANTHONY MANCINI
Officer
15,448 $3.2M
Aug 31, 2026 Lorence H Kim
Affiliate
73,090 $15.2M
Aug 21, 2026 THE JONATHAN GOLDSMITH REVOCABLE TRUST
Director, Officer
3,000 $635K
Aug 21, 2026 THE REBECCA GOLDSMITH REVOCABLE TRUST
Director, Officer
3,000 $635K
Aug 21, 2026 MARK A GOLDSMITH
Director, Officer
80,000 $16.9M
Aug 21, 2026 JEFFREY TODD CISLINI
Officer
75,894 $16.1M
Jun 29, 2026 SUSHIL PATEL
Director
5,580 $1.0M
Jun 24, 2026 JACK ANDERS
Officer
20,000 $3.4M
Jun 15, 2026 Mancini Anthony
Officer
4,211 $648K
Jun 15, 2026 Cislini Jeff
Officer
1,656 $255K
Jun 15, 2026 MARGARET A HORN
Officer
90,000 $13.8M
Jun 15, 2026 Anders Jack
Officer
2,653 $408K
Jun 15, 2026 Kelsey Stephen Michael
Officer
4,071 $626K
Jun 15, 2026 Horn Margaret A
Officer
3,486 $536K
Jun 15, 2026 GOLDSMITH MARK A
Officer, Director
9,772 $1.5M
Jun 11, 2026 MARGARET A HORN
Officer
10,000 $1.4M
May 26, 2026 ANTHONY MANCINI
Officer
3,121 $473K
Apr 27, 2026 ANTHONY MANCINI
Officer
3,120 $422K
Apr 15, 2026 MARK A GOLDSMITH
Director, Officer
120,000 $17.6M
Mar 26, 2026 Mancini Anthony
Officer
37,450 $3.6M
Mar 19, 2026 JEFFREY TODD CISLINI
Officer
1,163 $114K
Mar 13, 2026 Cislini Jeff
Officer
2,053 $204K
Mar 13, 2026 Wei Lin
Officer
2,288 $228K
Mar 13, 2026 Wang Xiaolin
Officer
2,282 $227K
Mar 13, 2026 Anders Jack
Officer
2,134 $213K
Mar 13, 2026 Kelsey Stephen Michael
Officer
3,901 $389K
Mar 13, 2026 Horn Margaret A
Officer
4,722 $470K
Mar 13, 2026 GOLDSMITH MARK A
Officer, Director
13,261 $1.3M
Mar 2, 2026 JONATHAN GOLDSMITH REVOCABLE TRUST
Director, Officer
3,000 $306K
Mar 2, 2026 THE REBECCA GOLDSMITH REVOCABLE TRUST
Director, Officer
3,000 $306K
Mar 2, 2026 MARK A GOLDSMITH
Director, Officer
30,000 $3.1M
Jan 21, 2026 JEFFREY TODD CISLINI
Officer
908 $106K
Jan 7, 2026 MARGARET A HORN
Officer
75,000 $6.0M
Jan 7, 2026 JACK LEE ANDERS
Officer
10,000 $798K
Dec 12, 2025 Cislini Jeff
Officer
2,614 $203K
Dec 12, 2025 Anders Jack
Officer
3,017 $235K
Dec 12, 2025 Kelsey Stephen Michael
Officer
5,296 $412K
Dec 12, 2025 Horn Margaret A
Officer
4,711 $367K
Dec 12, 2025 GOLDSMITH MARK A
Officer, Director
14,964 $1.2M
Nov 25, 2025 J H GOLDSMITH & M A GOLDSMITHCO-TTEE JONATHAN GOLDSMITH REV TRU/A/D 8/16/2023
Director, Officer
3,000 $221K
Nov 25, 2025 THE REBECCA GOLDSMITH REVOCABLE TRUST
Director, Officer
3,000 $221K
Nov 25, 2025 MARK A GOLDSMITH
Director, Officer
60,000 $4.4M
Nov 25, 2025 JACK LEE ANDERS
Officer
5,418 $399K
Nov 18, 2025 MARK A GOLDSMITH
Director, Officer
20,000 $1.4M
Nov 18, 2025 JEFFREY TODD CISLINI
Officer
13,388 $926K
Show the other 51 notices

From the Form 144 XML filed with the SEC, since Nov 18, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVMD/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.